Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 976 - 1000 of 14513 in total
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the...
Approved
Investigational
Matched Description: … Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors ... [A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as ... promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and
Matched Categories: … Serotonin antagonist and reuptake inhibitors (SARIs) …
Technetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands, hence the name sesta (6) MIBI.. Following intravenous injection of the drug, Technetium Tc-99m sestamibi is taken up by...
Approved
Investigational
Matched Description: … infarction (non-reversible defects); and 2) evaluating myocardial function and developing information ... intravenous injection of the drug, Technetium Tc-99m sestamibi is taken up by the myocardium, parathyroid, and ... indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and
Matched Categories: … Indicators and Reagents …
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Description: … Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX. ... [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Description: … It was superseded by [pioglitazone] and [rosiglitazone]. …
Matched Categories: … Alimentary Tract and Metabolism …
Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to...
Approved
Investigational
Matched Description: … [A447] Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic ... [L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002. …
Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does...
Approved
Investigational
Matched Description: … , such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety. ... Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. ... receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and
Matched Categories: … Miscellaneous Anxiolytics Sedatives and Hypnotics …
Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.
Approved
Matched Description: … Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and
Epicriptine is also known as beta-dihydroergocryptine presents a molecular formula of 9,10 alpha-dihydro-13'-epi-b-ergocryptine. Together with the alpha-dihydroergocryptine, it represents one-third of the ergoloid mesylate mixture. Epicriptine differs from the alpha form on the position of one methyl group. To know more about the mixture please visit DB01049
Approved
Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Description: … [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation. …
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline...
Approved
Investigational
Matched Description: … of serotonin reuptake and has little effect on other neurotransmitters. ... [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. ... uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a...
Approved
Investigational
Vet approved
Matched Description: … treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and ... of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis ... [A191787] Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment …
Matched Categories: … chloroquine and proguanil ... Antiparasitic Products, Insecticides and Repellents …
A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.
Approved
Investigational
Matched Description: … It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone …
Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.
Approved
Matched Description: … Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
A systemic agricultural fungicide and seed treatment agent.
Approved
Experimental
Matched Description: … A systemic agricultural fungicide and seed treatment agent. …
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Description: … is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and
Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Approved
Investigational
Matched Description: … new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and
Matched Categories: … Decongestants and Antiallergics …
Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Approved
Matched Description: … Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. ... water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.
Approved
Investigational
Matched Description: … Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial ... of action has not been described in the literature, though it positively modulates GABAA and
Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are shown to regulate...
Approved
Matched Description: … Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. ... It is a coordination complex consisting of chromium(III) and picolinic acid. ... Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity …
Boric acid, also known as hydrogen borate, is a weak monobasic Lewis acid of boron with the chemical formula H3BO3. Boric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive in pharmaceutical products, cosmetics, lotions, soaps, mouthwash, toothpaste, astringents, and eyewashes . It...
Approved
Matched Description: … It is known to exhibit some antibacterial activity against infections such as bacterial vaginosis and ... in pharmaceutical products, cosmetics, lotions, soaps, mouthwash, toothpaste, astringents, and eyewashes ... Boric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive …
Propolis wax is naturally produced by honeybees by mixing the resin or exudate collected from tree buds, sap flows, or other botanical sources with beeswax that contains fatty acids and bee enzymes. Propolis itself contains various chemical compounds including flavonoids, terpenoids, aldehydes, aromatic acids, aliphatic alcohols and ethers, amino acids,...
Approved
Matched Description: … ethers, amino acids, and sugars. ... collected from tree buds, sap flows, or other botanical sources with beeswax that contains fatty acids and ... chemical compounds including flavonoids, terpenoids, aldehydes, aromatic acids, aliphatic alcohols and
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval...
Approved
Investigational
Matched Description: … [L2933] It is administered orally and is odorless, tasteless, and stable at room temperature. ... Approval of the medication is supported by data from three double-blind, placebo-controlled trials and ... two open-label trials which showed that the onset of action was approximately 1.0 hour and the median …
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Approved
Experimental
Matched Categories: … Diet, Food, and Nutrition …
Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational
Matched Description: … [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly ... [A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times …
Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release.
Approved
Matched Description: … those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and ... thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release …
Displaying drugs 976 - 1000 of 14513 in total